Baqsimi® Nasal Glucagon 3 mg for Severe Hypoglycemia

What Baqsimi® Is and How It Works

Baqsimi® Nasal Powder is intranasal glucagon for the emergency treatment of severe hypoglycemia in people with diabetes aged 4 years and older. Each single-use device delivers a fixed 3 mg dose into one nostril. The powder does not require inhalation and can work even if the person is not breathing through the nose. Many people search for baqsimi nasal powder without insurance to compare options and plan for emergencies.

CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. We work with licensed, vetted partner pharmacies to supply authentic brand medications, a broad selection, and value‑focused pricing.

Glucagon is a counter-regulatory hormone. It raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. In severe hypoglycemia, timely glucagon can restore blood glucose while oral intake is not possible. Intranasal delivery removes the need for mixing a vial and syringe and can simplify caregiver use during stressful events.

Dosage and Usage

• Usual dose: one 3 mg device into a single nostril at the first signs of severe hypoglycemia (for adults and children 4 years and older).
• Administration: insert the tip gently into one nostril and press the plunger firmly until it clicks.
• No inhalation required: the dose is absorbed through the nasal mucosa even without active sniffing.
• After dosing: call for emergency help. If the person is unconscious, place on the side to reduce the risk of aspiration.
• Repeat dosing: if there is no response after 15 minutes, give a second 3 mg dose using a new device.
• Follow-up carbohydrates: once the person can swallow, give fast-acting carbohydrate, then a snack or meal to prevent recurrent hypoglycemia.
• Pediatric use: approved for children 4 years and older. The same 3 mg dose applies.
• Training: review the Instructions for Use with family or close contacts so they can administer the device quickly.
• Missed dose: Baqsimi is used as needed for severe hypoglycemia, not on a schedule.
• Do not test-spray or prime the device. Each unit contains a single dose only.

• Storage: keep at room temperature 20–25°C (68–77°F). Excursions 15–30°C (59–86°F) are permitted.
• Protect from moisture: keep sealed in the shrink-wrapped tube until needed. Do not open in advance.
• Do not freeze or refrigerate. Avoid excessive heat or humidity.
• Check the expiration date regularly and replace before it expires.
• Travel: carry in hand luggage; avoid leaving in a hot car. Keep an extra device during longer trips.
• Emergency readiness: inform travel companions where your device is kept and how to use it.

Benefits and Savings

Intranasal delivery helps caregivers act fast without mixing or needles. The fixed 3 mg dose simplifies administration across adult and pediatric patients 4+. The compact, single-use device fits in a pocket or kit and can be used even if nasal breathing is limited. Many customers save 60–80% vs typical U.S. prices. This can help those paying cash, including baqsimi nasal powder without insurance.

See our promotions page for current offers, including any baqsimi nasal powder coupon if available.

Side Effects and Safety

• Common: nausea, vomiting, headache, dizziness.
• Nasal/throat: runny or stuffy nose, nasal discomfort, sneezing, cough, throat irritation, watery eyes, redness.
• Other: transient increases in heart rate or blood pressure, fatigue.

Serious reactions are uncommon but can include hypersensitivity or anaphylaxis. Do not use in people with pheochromocytoma due to risk of marked hypertension, or in those with insulinoma because hypoglycemia may worsen. Glucagon may be less effective in prolonged fasting, adrenal insufficiency, or chronic hypoglycemia. Beta-blockers can enhance pulse/BP changes; indomethacin may reduce glucose response. Recurrent low glucose risk remains with insulin or sulfonylureas until food is given and background therapy is adjusted.

Onset Time

Blood glucose usually begins to rise within about 5–15 minutes after intranasal dosing. Clinical recovery signs, such as improved alertness, may follow as glucose increases. If there is no noticeable response after 15 minutes, a second 3 mg dose from a new device is recommended while seeking medical care. Give oral carbohydrates as soon as swallowing is safe to maintain glucose levels.

Compare With Alternatives

Glucagon injection kits require mixing a powder and diluent, then an intramuscular or subcutaneous injection. Many caregivers prefer the simplicity of a nasal device during emergencies. For those comfortable with injections, a Glucagon Injection Kit With Diluent may be a cost-conscious alternative and has similar clinical effectiveness when used correctly.

Prefilled glucagon options and autoinjector formats exist in some markets. These can reduce steps compared with traditional kits, but availability and pricing vary. Intranasal glucagon removes needles entirely, which may help bystanders act faster and with more confidence in real-world situations. Consider device familiarity, the setting (home, school, workplace), and who is most likely to administer treatment when choosing an emergency glucagon format.

Combination Therapy

• Basal-bolus insulin: keep glucagon accessible at home, work, and school; educate caregivers.
• Insulin plus sulfonylurea: higher hypoglycemia risk may warrant carrying multiple devices.
• Insulin pump therapy: maintain glucagon on hand during site failures or illness.
• Background dose adjustments: clinicians may lower insulin or sulfonylurea doses after a severe event to reduce recurrence risk.
• Post-event care: resume oral carbohydrates and usual monitoring once alert and able to swallow.

Patient Suitability and Cost-Saving Tips

Candidates include adults and children 4 years and older with diabetes who are at risk of severe hypoglycemia. Not suitable for those with pheochromocytoma or insulinoma. Effectiveness may be limited in prolonged fasting, adrenal insufficiency, or chronic hypoglycemia. Caregiver training and device familiarity are essential for safe, timely use.

Practical savings tips include keeping more than one device for home and travel, using multi-month orders when appropriate, and setting gentle reminders to reorder before expiration. Storing in original sealed packaging preserves shelf life and reduces waste. For schools or workplaces, coordinating a plan with staff can ensure devices are available where needed.

Authoritative Sources

Manufacturer information for Baqsimi (Eli Lilly)

FDA Prescribing Information and Medication Guide

Health Canada Drug Product Database (DPD) search

Order Baqsimi from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This page is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any questions regarding a medical condition or medication.